<p>aTyr Pharma, Inc. (NASDAQ:ATYR - 獲取免費報告) 在 12 月份經歷了顯著的空頭頭寸下降。截至 12 月 31 日，空頭頭寸總計為 25,013,857 股，比 12 月 15 日的 30,385,566 股下降了 17.7%。根據平均每日交易量 2,246,751 股，目前的空頭頭寸比率為 11.1 天。大約 26.5% 的公司股份被做空。</p>
<h2>對 aTyr Pharma 的對沖基金看法</h2>
<p>幾家對沖基金和其他機構投資者最近調整了對該股票的持有。加利福尼亞州教師退休系統在第二季度購買了 aTyr Pharma 的新頭寸，價值約 28,000 美元。Ameritas Investment Partners Inc.在第二季度購買了 aTyr Pharma 的股份，價值約 45,000 美元。Legal &amp; General Group Plc 在第二季度購買了 aTyr Pharma 的股份，價值約 49,000 美元。Prudential Financial Inc.在第二季度購買了 aTyr Pharma 的股份，價值約 63,000 美元。最後，Oxford Asset Management LLP 在第二季度購買了 aTyr Pharma 的股份，價值約 70,000 美元。對沖基金和其他機構投資者持有公司 61.72% 的股票。</p>
<h2>aTyr Pharma 股票表現</h2>
<p>ATYR 股票週一開盤價為 0.71 美元。aTyr Pharma 的 52 周低點為 0.64 美元，52 周高點為 7.29 美元。該公司的市值為 6944 萬美元，市盈率為-0.85，貝塔值為 0.60。該公司的 50 日移動平均價格為 0.74 美元，200 日移動平均價格為 2.49 美元。</p>
<p>aTyr Pharma (NASDAQ:ATYR - 獲取免費報告) 最近於 11 月 6 日宣佈了季度財報。公司報告季度每股收益為（0.26 美元），低於分析師一致預期的（0.20 美元）6 美分。該季度的收入為 19 萬美元，而一致預期為 91 萬美元。整體來看，股票分析師預測 aTyr Pharma 在本年度將發佈-0.91 的每股收益。</p>
<h2>華爾街分析師看法</h2>
<p>另外，Weiss Ratings 在 12 月 29 日的研究報告中重新發布了對 aTyr Pharma 股票的 “賣出（d-）” 評級。一位分析師給予該股票買入評級，六位分析師給予持有評級，一位分析師給予賣出評級。根據 MarketBeat 的數據，該股票的平均評級為 “持有”，平均目標價格為 23.25 美元。</p>
<p><strong>查看我們對 ATYR 的最新分析</strong></p>
<h2>關於 aTyr Pharma</h2>
<p>(獲取免費報告)</p>
<p>aTyr Pharma, Inc 是一家臨牀階段的生物技術公司，專注於發現和開發調節細胞外基質和免疫通路的新型蛋白質療法。公司總部位於加利福尼亞州聖地亞哥，利用其專有的細胞外調節®平台，識別和優化生物治療候選藥物，以治療罕見和嚴重疾病，包括肺肉芽腫病、肌肉萎縮症和實體腫瘤。</p>
<p>公司的研究工作集中在利用細胞外蛋白質調節組織重塑、細胞粘附和免疫信號傳導。</p>
<h2>特色文章</h2>
<ul>
<li>我們更看好的五隻股票比 aTyr Pharma 更好</li>
<li>Elon 將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>用這四個簡單步驟 “防止美聯儲影響” 您的銀行賬户</li>
<li>新法律：國會批准數字美元的設立？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 aTyr Pharma 嗎？</h2>
<p>在您考慮 aTyr Pharma 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前立即購買……而 aTyr Pharma 並不在名單上。</p>
<p>雖然 aTyr Pharma 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

LIFE

<p>aTyr Pharma, Inc.（納斯達克代碼：ATYR）在空頭頭寸方面經歷了顯著下降，截至 12 月 31 日下降了 17.7%，降至 25,013,857 股。該公司約有 26.5% 的股票被做空，覆蓋天數比率為 11.1 天。對沖基金增加了其持倉，持有 61.72% 的股票。該公司的股票開盤價為 0.71 美元，市值為 6944 萬美元。分析師對該股票給予持有評級，平均目標價為 23.25 美元</p>

<p>aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling 25,013,857 shares, a drop of 17.7% from the December 15th total of 30,385,566 shares. Based on an average daily volume of 2,246,751 shares, the short-interest ratio is currently 11.1 days. Approximately 26.5% of the company's shares are short sold. Approximately 26.5% of the company's shares are short sold. Based on an average daily volume of 2,246,751 shares, the short-interest ratio is currently 11.1 days.</p>
<div class="lb-trans"><p>aTyr Pharma, Inc. (NASDAQ:ATYR - 獲取免費報告) 在 12 月份經歷了顯著的空頭頭寸下降。截至 12 月 31 日，空頭頭寸總計為 25,013,857 股，比 12 月 15 日的 30,385,566 股下降了 17.7%。根據平均每日交易量 2,246,751 股，目前的空頭頭寸比率為 11.1 天。大約 26.5% 的公司股份被做空。</p>
</div><h2>Hedge Funds Weigh In On aTyr Pharma</h2>
<div class="lb-trans"><h2>對 aTyr Pharma 的對沖基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System bought a new position in aTyr Pharma in the second quarter worth about $28,000. Ameritas Investment Partners Inc. purchased a new position in shares of aTyr Pharma during the 2nd quarter worth approximately $45,000. Legal &amp; General Group Plc bought a new position in shares of aTyr Pharma in the 2nd quarter worth approximately $49,000. Prudential Financial Inc. bought a new position in shares of aTyr Pharma in the 2nd quarter worth approximately $63,000. Finally, Oxford Asset Management LLP purchased a new position in shares of aTyr Pharma in the 2nd quarter valued at approximately $70,000. Hedge funds and other institutional investors own 61.72% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近調整了對該股票的持有。加利福尼亞州教師退休系統在第二季度購買了 aTyr Pharma 的新頭寸，價值約 28,000 美元。Ameritas Investment Partners Inc.在第二季度購買了 aTyr Pharma 的股份，價值約 45,000 美元。Legal &amp; General Group Plc 在第二季度購買了 aTyr Pharma 的股份，價值約 49,000 美元。Prudential Financial Inc.在第二季度購買了 aTyr Pharma 的股份，價值約 63,000 美元。最後，Oxford Asset Management LLP 在第二季度購買了 aTyr Pharma 的股份，價值約 70,000 美元。對沖基金和其他機構投資者持有公司 61.72% 的股票。</p>
</div><h2>aTyr Pharma Stock Performance</h2>
<div class="lb-trans"><h2>aTyr Pharma 股票表現</h2>
</div><p>Shares of ATYR stock opened at $0.71 on Monday. aTyr Pharma has a fifty-two week low of $0.64 and a fifty-two week high of $7.29. The firm has a market cap of $69.44 million, a P/E ratio of -0.85 and a beta of 0.60. The business's 50 day moving average price is $0.74 and its 200-day moving average price is $2.49.</p>
<div class="lb-trans"><p>ATYR 股票週一開盤價為 0.71 美元。aTyr Pharma 的 52 周低點為 0.64 美元，52 周高點為 7.29 美元。該公司的市值為 6944 萬美元，市盈率為-0.85，貝塔值為 0.60。該公司的 50 日移動平均價格為 0.74 美元，200 日移動平均價格為 2.49 美元。</p>
</div><p>aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.06). The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.91 million. As a group, equities analysts predict that aTyr Pharma will post -0.91 EPS for the current year.</p>
<div class="lb-trans"><p>aTyr Pharma (NASDAQ:ATYR - 獲取免費報告) 最近於 11 月 6 日宣佈了季度財報。公司報告季度每股收益為（0.26 美元），低於分析師一致預期的（0.20 美元）6 美分。該季度的收入為 19 萬美元，而一致預期為 91 萬美元。整體來看，股票分析師預測 aTyr Pharma 在本年度將發佈-0.91 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師看法</h2>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of aTyr Pharma in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of &#34;Hold&#34; and an average price target of $23.25.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 12 月 29 日的研究報告中重新發布了對 aTyr Pharma 股票的 “賣出（d-）” 評級。一位分析師給予該股票買入評級，六位分析師給予持有評級，一位分析師給予賣出評級。根據 MarketBeat 的數據，該股票的平均評級為 “持有”，平均目標價格為 23.25 美元。</p>
</div><p><strong>View Our Latest Analysis on ATYR</strong></p>
<div class="lb-trans"><p><strong>查看我們對 ATYR 的最新分析</strong></p>
</div><h2>About aTyr Pharma</h2>
<div class="lb-trans"><h2>關於 aTyr Pharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.</p>
<div class="lb-trans"><p>aTyr Pharma, Inc 是一家臨牀階段的生物技術公司，專注於發現和開發調節細胞外基質和免疫通路的新型蛋白質療法。公司總部位於加利福尼亞州聖地亞哥，利用其專有的細胞外調節®平台，識別和優化生物治療候選藥物，以治療罕見和嚴重疾病，包括肺肉芽腫病、肌肉萎縮症和實體腫瘤。</p>
</div><p>The company's research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.</p>
<div class="lb-trans"><p>公司的研究工作集中在利用細胞外蛋白質調節組織重塑、細胞粘附和免疫信號傳導。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than aTyr Pharma</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 aTyr Pharma 更好</li>
<li>Elon 將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>用這四個簡單步驟 “防止美聯儲影響” 您的銀行賬户</li>
<li>新法律：國會批准數字美元的設立？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in aTyr Pharma Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 aTyr Pharma 嗎？</h2>
</div><p>Before you consider aTyr Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 aTyr Pharma 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and aTyr Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前立即購買……而 aTyr Pharma 並不在名單上。</p>
</div><p>While aTyr Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 aTyr Pharma 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

aTyr Pharma, Inc.（納斯達克股票代碼：ATYR）空頭頭寸大幅減少